141P Clinical study of camrelizumab combined with SOX in adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma: Interim report
Background: D2 gastrectomy is the treatment of choice for resectable gastric cancer in East Asia.Existing evidence shows that adjuvant chemotherapy after surgery can improve patient survival.To further extend the disease-free survival (DFS) of gastric cancer patients, our study explores the synergistic effect of combining PD-1 inhibitor camrelizumab with the SOX regimen in the adjuvant treatment setting. Conclusions:The combination of camrelizumab and the SOX regimen shows good potential for adjuvant therapy.The 2-year DFS rate is better than controls and has a controllable safety profile.Systemic inflammation markers (RDW/NLR) may serve as potential prognostic biomarkers.However, due to the limited number of events, further follow-up is needed.Clinical trial identification: NCT05184946.
Authors
- C. Su
- M. Li
- H. Liu
- Z. Xiao
- K. Li
- Q. Li
- Y. Kong
- L. Ma
- C. Wei
- M. Jiao
- Y. Wen
- Q. Yi
- J. Liu
- C. Wang
Institutions
- Second Hospital of Shandong University (CN)
- Affiliated Hospital of Taishan Medical University (CN)
- Taizhou First People's Hospital (CN)
- Taian City Central Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101225
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vanderbilt University
- Ohio State University
- Northwestern University
- University of Pittsburgh
- McGill University
- Moffitt Cancer Center
- Vanderbilt University Medical Center
- McGill University Health Centre
- School of Medicine, Stanford University
- University of Texas MD Anderson Cancer Center
- Medical Center, University of Pittsburgh
- University of Colorado Denver
- Jonsson Comprehensive Cancer Center